Hyderabad, Mar 14: Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope–labelled compounds, in collaboration with Hyderabad-based speciality chemicals manufacturer Chemtatva Chiral Solutions Pvt Ltd., has announced a strategic joint venture to establish advanced manufacturing capabilities in Telangana.

The joint venture plans to invest up to ₹300 crore over the next three years in Genome Valley Phase 4, creating over 250 direct, high-skilled jobs and strengthening India’s position in manufacturing isotopically labelled molecules used in pharmaceutical research, diagnostics, advanced electronics, OLED materials, and semiconductor applications.

The announcement follows a meeting between the company delegation and Telangana’s Minister for IT, Electronics & Communications, Industries & Commerce and Legislative Affairs, Duddilla Sridhar Babu, along with CEO of Telangana Life Sciences, Shakthi M. Nagappan, in Hyderabad. The company delegation included Cliff Caldwell, CEO CIL Inc., along with John Bakke, CFO CIL Inc., Gregory Whitney, VP-Sales and Marketing CIL Inc., Vishal Rajput, CEO Chemtatva Chiral Solutions Pvt Ltd., and Vinod Kumar, Director Chemtatva.

Despite receiving interest from several other states, the companies chose Telangana, citing the state’s strong life sciences ecosystem, availability of skilled scientific talent, robust infrastructure, and proactive government support for advanced manufacturing sectors.

Welcoming the investment, Shri D. Sridhar Babu said: “Telangana is steadily emerging as a global destination for high-value manufacturing in life sciences and speciality chemicals. The partnership between Cambridge Isotope Laboratories and

Chemtatva reflects the confidence global innovators have in Telangana’s ecosystem. This investment will strengthen our capabilities in advanced chemistry and materials while creating high-skilled jobs and expanding our industrial base.”

Shakthi M. Nagappan, CEO of Telangana Life Sciences, highlighted the strategic importance of the investment: “Stable isotopes and labelled molecules are essential tools for modern pharmaceutical research, diagnostics, and emerging electronics applications. The proposed facility will manufacture a wide range of stable isotope–labelled compounds that are critical for drug discovery, metabolic studies, diagnostics, and advanced materials research. This investment will also help reduce India’s dependence on imports in this highly specialised segment of the life sciences and advanced materials industry.”

Dr Vishal Rajput, Founder & CEO of Chemtatva Chiral Solutions Pvt Ltd., said:

“Over the past five years, Chemtatva has grown into a leading player in the stable isotopes space while creating more than 100 direct jobs. Partnering with Cambridge Isotope Laboratories enables us to combine global expertise with India’s scientific talent to build world-class manufacturing capabilities in Telangana. This investment will significantly expand our capacity and allow us to serve global pharmaceutical and advanced materials customers.”

Mr Cliff Caldwell, CEO, Cambridge Isotope Laboratories, said: “Telangana offers a strong ecosystem for advanced chemistry and life sciences manufacturing, supported by a skilled scientific workforce and progressive policies. Through this collaboration with Chemtatva, we look forward to expanding our global manufacturing network and delivering high-quality isotopically labelled compounds to customers around the world.”

Once operational, the facility is expected to strengthen India’s position in global supply chains for pharmaceutical research tools and advanced electronic materials, further reinforcing Telangana’s reputation as a leading hub for life sciences and speciality chemicals manufacturing.